Regimens for intestinal transplant immunosuppression

Current Opinion in Organ Transplantation

Volumn 10, Issue 2, 2005, Pages 120-123

  Fishbein, Thomas M ^a,b   Matsumoto, Cal S ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Immunosuppression; Infliximab; Interlukin 2 receptor antagonists; Intestinal transplantation; Multivisceral transplantation; Sirolimus

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; CAUSE OF DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTESTINE; INTESTINE GRAFT; INTESTINE TRANSPLANTATION; NONHUMAN; REVIEW; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VIRUS VIRULENCE;

EID: 21044451730     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000163724.38586.d1     Document Type: Review

References (34)

1. Starzl TE, Kaupp HA Jr, Brock DR. Homotransplantation of multiple visceral organs. Am J Surg 1959; 150:543-560.
2. Lillehi RC, Idezuki Y, Feemster JA, et al. Transplantation of stomach, intestine, and pancreas:experimental and clinical observations. Surgery 1967; 62: 721-741.
3. Deterling R, Discussion of paper by Alican F, Hardy JD, et al. Intestinal transplantation: laboratory experience and a report of a clinical case. Am J Surg 1971; 99:121-150.
4. McAlister VC, Grant DR. Clinical small bowel transplanatation. In Small Bowel Transplantation. Edited by Grant DR, Wood RF. London:Edward Arnold Publishing; 1994:122
5. Dudrick SJ, Wilmore DW, Vars HM, et al. Long term parenteral nutrition with growt, development, and positive nitrogen balance. Surgery 1968; 64:134-142.
6. Colomb V, Goult O, Ronbaud C, et al. Long term parenteral nutrition in children:liver and gallbladder disease. Transplant Proc 1992; 24:1054-1055.
7. Vanhuynegen L, Parmentier P, Portulige CA. In place bacteriologic diagnosis of total parenteral nutrition catheter infection. Surgery 1988; 103:174-177.
8. Fishbein TM, Gondolesi GE, Kaufman SS. Intestinal transplantation for gut failure. Gastroenterology 2003; 124:1615-1628.
9. Starzl TE, Rowe MI, Todo S, et al. Transplantation of multiple abdominal viscera. JAMA 1989; 261:1449-1457.
10. Grant D, Wall W, Mimeault R, et al. Successful small-bowel/liver transplantation. Lancet 1990; 335:181-184.
11. Deltz E, Schroder P, Gebhart H, et al. Successful clinical small intestine transplantation: report of a case. Clin Transplant 1989; 3:89-91.
12. Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantions. Ann Surg 1995; 222:270.
13. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg 2001; 234:404-417.
14. Nishida S, Levi D, Kato T, et al. Ninety-five cases of intestinal transplantation at the University of Miami. J Gastrointest Surg 2002; 6:233-239.
15. Fishbein TM. The current state of intestinal transplantation. Transplantation 2004; 78:175-178. A concise review of the latest developments in intestinal transplantation and outlines future challenges in the field.
16. Mueller AR, Pascher A, Platz KP, et al. Imunosupression following intestinal transplantation. Transplant Proc 2004; 36:325-328.
17. Masetti M, Cautero N, Lauro A, et al. Three-year experience in clinical intestinal transplantation. Transplant Proc 2004; 36:309-311.
18. Fishbein TM, Gondolesi GE, Kaufman SS. Intestinal Transplantation for gut failure. Gastroenterology 2003; 124:1615-1628.
19. Grant D. Intestinal Transplantation: 1997 reposrt of the international registry: Intestinal transplant Registry. Transplantation 1999; 67:1061-1064.
20. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29:404-430.
21. Matsuda S, Uemoto S, Goto M, et al. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther 2004; 75:352-361.
22. Farmer DG, McDiarmid SV, Edelstein S, et al. Induction therapy with interleukin-2 receptor antagonist after intestinal transplantation is assoiated with reduced acute cellular rejection and improved renal function. Transplant Proc 2004; 36:331-332. A brief, retrospective analysis of 27 intestinal allograft recipients and outcomes based on differing induction protocols.
23. Sudan DL, Chinnakotla S, Horslen S, et al. Basiliximab decreases the incidence of acute rejection after intestinal transplantation. Transplant Proc 2002; 34:940-941.
24. Kato T, Gaynor J, Selvaggi G, et al. Intestinal transplantation in children: A summary of clinical outcomes and prognostic factors in 108 patients from a single center. J Gastrointest Surg 2005; 9:75-89. This is a 10-year summary of the University of Miami/Jackson Memorial Hospital pediatric intestinal transplant experience. The authors detail the entire immunosuppression experience as well as give a comprehensive analysis of prognostic factors.
25. Reyes J, Mazariegos GV, Bond G, et al. Rabbit anti-thymocyte (RATG) preconditioning and induction for pediatric intestine transplantation. Am J of Transpl 2004; 4(Supp 8):536. ([abstract])
26. Simpson D. T-cell depleting antibodies:new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs 2003; 17:147-154.
27. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath-1H and low-dose cyclosporine monotheraphy in renal allograft recipients. Lancet 1998;351:1701-1702.
28. Tzakis AG, Kato T, Nishida S, et al. Preliminary experience with campath-1H in intestinal and liver transplantation. Transplantation 2003; 75:1227-1231.
29. Garcia M, Weppeler N, Mittal S, et al. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant Proc 2004; 36:323-324. A summary of the results of early post-transplant incidence of acute rejection between campath-1H and daclizumab induction therapy.
30. Ruiz P, Soares MF, Garcia M, et al. Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving campath immunosuppression. Transplant Proc 2004; 36:386-387.
31. Fishbein TM, Florman S, Gondolesi G, et al. Intestinal transplantation before and after the introduction of sirolimus. Transplantation 2002; 73:1538.
32. Paramesh A, Grosskreutz C, Florman S, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004; 77:129-131. A brief communication noting the clinical findings of the rare complication of thrombotic microangiopathy from sirolimus and tacrolimus in intestinal transplantation and the results of withdrawing sirolimus for treatment.
33. Pascher A, Radke C, Dignass A, et al. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. Transplantation 2003; 76:615-618.
34. Wu T, Abu-Elmagd K, Bond G, et al. A clinicopathological study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol 2004; 35:1332-1339. An excellent review of the description of intestinal humoral rejection, and immunosuppression strategies to treat this condition.